Current report, item 5.07



bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">









UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549










FORM 8-K












CURRENT REPORT


Pursuant to Section 13 or 15(d)


of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):

June 24,
2021







CYCLERION THERAPEUTICS, INC.


(Exact name of registrant as specified in its charter)



























Massachusetts



001-38787



83-1895370






(State or other jurisdiction of incorporation)



(Commission File Number)



(IRS Employer Identification Number)







245 First Street, 18th Floor


Cambridge, Massachusetts 02142






(Address of principal executive offices, including Zip Code)


Registrant’s telephone number, including area code:

(857)
327-8778







Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:


















Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

















Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

















Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

















Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Securities registered pursuant to Section 12(b) of the Act:




























Title of each class






Trading Symbol(s)






Name of each exchange on which registered









Common Stock, no par value




CYCN




The Nasdaq Stock Market LLC


(Nasdaq Global Select Market)





Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒






If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐























Item 5.07.


Submission of Matters to a Vote of Security Holders.






At Cyclerion Therapeutics, Inc.’s (the “Company”) annual meeting
of stockholders held on June


24


, 2021, as
contemplated by the Company’s definitive proxy material for the meeting, certain matters were submitted to a vote of stockholders.  The following tables summarize the results of voting with respect to each matter:







1.  Election of Directors:













































































































For




Against




Withheld




Broker


Non-Votes



Kevin Churchwell, M.D.



20,034,155




0




57,455




4,025,472



George Conrades



20,011,263




0




80,347




4,025,472



Errol De Souza, Ph.D.



19,388,700




0




702,910




4,025,472



Marsha Fanucci



19,598,737




0




492,873




4,025,472



Peter M. Hecht, Ph.D.



19,948,022




0




143,588




4,025,472



Ole Isacson, M.D., Ph.D.



20,033,506




0




58,104




4,025,472



Stephanie Lovell



20,064,598




0




27,012




4,025,472



Terrance McGuire



20,000,066




0




91,544




4,025,472



Michael Mendelsohn, M.D.



20,038,610




0




53,000




4,025,472







2.

Ratification of the appointment of Ernst & Young LLP
as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021:

























For




Against




Abstain



23,981,513




132,953




2,616











2









SIGNATURES





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.

































Cyclerion Therapeutics, Inc.






Dated: June 25, 2021



By:



/s/ Anjeza Gjino





Name:



Anjeza Gjino





Title:



Chief Financial Officer













3






The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Cyclerion Therapeutics, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Current report, items 7.01 and 9.01 - Sept. 30, 2021

Auto Refresh

Feedback